A phase I study to evaluate the safety and tolerability of SX-682 in combination with PD-1 inhibitor as maintenance therapy for unresectable pancreatic adenocarcinoma

被引：5
|
作者：
Dunne, Richard Francis
Ullman, Nicholas A.
Belt, Brian A.
Ruffolo, Luis I.
Burchard, Paul
Hezel, Aram F.
Zittel, Jason
Wang, Wenjia
Ramsdale, Erika E.
Kaul, Vivek
Zebala, John
Linehan, David
机构：
[1] Univ Rochester, Med Ctr, Wilmot Canc Inst, Rochester, NY 14642 USA
[2] Univ Rochester, Med Ctr, Dept Surg, Rochester, NY 14642 USA
[3] Univ Rochester, Med Ctr, Dept Med, Div Gastroenterol, Rochester, NY 14642 USA
[4] Syntrix Pharmaceut, Auburn, WA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.TPS631
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS631
引用
收藏
页数：3
相关论文
共 50 条
  • [31] A phase 2 study to evaluate the safety and efficacy of Intratumoral (IT) injection of the TLR9 agonist IMO-2125 (IMO) in combination with ipilimumab (ipi) in PD-1 inhibitor refractory melanoma
    Diab, Adi
    Rahimian, Shah
    Haymaker, Cara L.
    Bernatchez, Chantale
    Andtbacka, Robert Hans Ingemar
    James, Marihella
    Johnson, Douglas Buckner
    Markowitz, Joseph
    Murthy, Ravi
    Puzanov, Igor
    Shaheen, Montaser F.
    Swann, Suzanne
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] Safety, tolerability, and effectiveness of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in combination with standard chemotherapy for patients with advanced, inoperable pancreatic adenocarcinoma: a phase 1b observational study
    Park, Lauren K.
    Lim, Kian-Huat
    Volkman, Jonas
    Abdiannia, Mina
    Johnston, Hannah
    Nigogosyan, Zack
    Siegel, Marilyn J.
    McGill, Janet B.
    McKee, Alexis M.
    Salam, Maamoun
    Zhang, Rong M.
    Ma, Da
    Popuri, Karteek
    Chow, Vincent Tze Yang
    Beg, Mirza Faisal
    Hawkins, William G.
    Peterson, Linda R.
    Ippolito, Joseph E.
    CANCER & METABOLISM, 2023, 11 (01)
  • [33] Safety, tolerability, and effectiveness of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in combination with standard chemotherapy for patients with advanced, inoperable pancreatic adenocarcinoma: a phase 1b observational study
    Lauren K. Park
    Kian-Huat Lim
    Jonas Volkman
    Mina Abdiannia
    Hannah Johnston
    Zack Nigogosyan
    Marilyn J. Siegel
    Janet B. McGill
    Alexis M. McKee
    Maamoun Salam
    Rong M. Zhang
    Da Ma
    Karteek Popuri
    Vincent Tze Yang Chow
    Mirza Faisal Beg
    William G. Hawkins
    Linda R. Peterson
    Joseph E. Ippolito
    Cancer & Metabolism, 11
  • [34] Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study
    Yoshikawa, Akie Kimura
    Yamaguchi, Kensei
    Muro, Kei
    Takashima, Atsuo
    Ichimura, Takashi
    Sakai, Daisuke
    Kadowaki, Shigenori
    Chin, Keisho
    Kudo, Toshihiro
    Mitani, Seiichiro
    Kitano, Shigehisa
    Dung Thai
    Zavodovskaya, Marianna
    Liu, JieJane
    Boku, Narikazu
    Satoh, Taroh
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (01)
  • [35] PD-1 inhibitor combined with lenvatinib for unresectable liver cancer as the conversion therapy: An open-label, non-randomized, phase IV study.
    Zhang, Wenwen
    Lu, Shichun
    Hu, Bingyang
    Wan, Tao
    Wang, Hongguang
    Han, Jun
    Zhang, Ze
    Cao, Junning
    Xin, Xianlei
    Pan, Yingwei
    Hu, Minggen
    Chen, Mingyi
    Chen, Yongliang
    Yang, Zhanyu
    Cai, Shouwang
    Ji, Wenbin
    Li, Chenggang
    Tong, Shuang
    Zhao, Feilong
    Zhao, Xiaochen
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] A phase Ib dose escalation, safety, and tolerability study of sonidegib in combination with gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma.
    Macarulla, Teresa
    Tabernero, Josep
    Palmer, Daniel H.
    Sharma, Sunil
    Yu, Kenneth H.
    Sellami, Dalila B.
    Zhou, Jocelyn
    Yi, Wu
    Boss, Hildegard
    Kwak, Eunice L.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [37] PHASE 1 STUDY OF THE PORCUPINE (PORCN) INHIBITOR RXC004 IN COMBINATION WITH THE PD-1 INHIBITOR NIVOLUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS
    Cook, Natalie
    Blagden, Sarah
    Lopez, Juanita
    Sarker, Debashis
    Greystoke, Alastair
    Bashir, Saira
    Skolariki, Aglaia
    ElBadri, Salma
    Morton, Cienne
    OrtegoFranco, Ana
    MohamedKhan, Shybi
    Eagle, Catherine
    Flanagan, Eimear
    Goodwin, Louise
    Phillips, Caroline
    Robertson, Jane
    Tilston, Craig
    Timmis, Helen
    Woodcock, Simon
    Plummer, Ruth
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A752 - A752
  • [38] Phase I Study of Chemoradiation Therapy (nab-Paclitaxel/Gemcitabine) in 18 Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma
    Ioka, Tatsuya
    Katayama, Kazuhiro
    Hibino, Kenji
    Yutaro, Abe
    Tamura, Takeshi
    Takada, Ryoji
    Fukutake, Nobuyasu
    Ashida, Reiko
    Ohkawa, Kazuyoshi
    Akita, Hiroshi
    Takahashi, Hidenori
    Hirata, Takero
    Teshima, Teruki
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 : 147 - 147
  • [39] A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours
    Desai, Jayesh
    Fong, Peter
    Moreno, Victor
    Frentzas, Sophia
    Meniawy, Tarek
    Markman, Ben
    Voskoboynik, Mark
    Rahman, Tahmina
    Budha, Nageshwar
    Wu, John
    Marlow, Jin
    Yang, Silu
    Calvo, Emiliano
    Martin-Liberal, Juan
    BRITISH JOURNAL OF CANCER, 2023, 128 (08) : 1418 - 1428
  • [40] A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours
    Jayesh Desai
    Peter Fong
    Victor Moreno
    Sophia Frentzas
    Tarek Meniawy
    Ben Markman
    Mark Voskoboynik
    Tahmina Rahman
    Nageshwar Budha
    John Wu
    Jin Marlow
    Silu Yang
    Emiliano Calvo
    Juan Martin-Liberal
    British Journal of Cancer, 2023, 128 : 1418 - 1428
12345